Trials / Completed
CompletedNCT01760122
Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B
A Phase 3, Randomized, Multi-center, Active-controlled, Open-label Study to Evaluate the Efficacy and Safety of Peginterferon Alfa-2b (40kD, Y Shape) in Chinese Chronic Hepatitis B Patients.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 820 (actual)
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is aimed to assess the efficacy and safety of Peginterferon alfa-2b (40kD, Y-shape), in a dose of 180μg/week, in chronic hepatitis B patients, and collects sufficient evidences for the listed of the studied drug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ypeginterferon alfa-2b | sc, qw, 48 weeks. |
| DRUG | Pegasys | sc, qw, 48 weeks. |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2015-07-01
- Completion
- 2015-08-01
- First posted
- 2013-01-03
- Last updated
- 2015-08-31
Locations
43 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01760122. Inclusion in this directory is not an endorsement.